FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912311235> ?p ?o ?g. }

• W2912311235 endingPage "e549" @default.
• W2912311235 startingPage "e548" @default.
• W2912311235 abstract "In a new study in The Lancet Global Health, John Ojal and colleagues1Ojal J Griffiths U Hammitt LL et al.Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.Lancet Glob Health. 2019; 7: e646-e656Summary Full Text Full Text PDF Scopus (10) Google Scholar project that the use of ten-valent pneumococcal conjugate vaccine (PCV10) will be cost-effective in Kenya after international donor support for vaccine programmes ends in around 2027. Until now, Kenya has relied on funding from Gavi, the international vaccine alliance, to fund its PCV programme. But because Gavi withdraws support from countries as their economies grow, Kenya will have to bear the full $9 per child cost for a three-dose course of PCVs starting in 2027. For Kenya, where annual per capita actual expenditure for health is around $70 (about 5% of GDP), that is not a trivial cost.2World BankWorld Development Indicators.Available from https://databank.worldbank.org/data/reports.aspx?source=World-Development-IndicatorsDate accessed: December 23, 2018Google Scholar Kenya is not alone in having to decide whether expensive vaccines are worth the money, as many other lower-middle-income countries with growing economies will soon lose international support. For these countries, careful evaluation of the cost-effectiveness and affordability of such programmes, and how they hold up against alternative investments in population health, are essential.3Cohen O Muralidharan K Gorham K et al.Gap analysis of PCV impact evaluations in settings of routine use.https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/PCVImpactAnalysis_PublicVersion_2017feb28.pdfDate: 2017Date accessed: December 23, 2018Google Scholar The current study is a much-appreciated effort to provide important insights to countries around the world as they struggle to decide how best to spend scarce resources. In their study, Ojal and colleagues used a sophisticated age-structured dynamic disease model to project the costs and benefits of continuing the Kenya PCV10 vaccine programme between 2022 and 2032, compared with letting the programme lapse.1Ojal J Griffiths U Hammitt LL et al.Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.Lancet Glob Health. 2019; 7: e646-e656Summary Full Text Full Text PDF Scopus (10) Google Scholar The model relied on pneumococcal surveillance, case incidence, and case fatality data for invasive pneumococcal disease (IPD) and severe pneumonia from a large hospital in Kifili. The model accounted for serotype replacement and assessed both direct and indirect vaccine benefits, such as those for older children and seniors. The researchers noted that in 2032, the PCV programme would cost about $150 for every disability-adjusted life-year (DALY) it averts, and have an annual programme cost of about $18 million. The researchers applied an often-used criterion for cost-effectiveness: is the cost per DALY averted less than the per-capita GDP?4Bertram MY Lauer JA De Joncheere K et al.Cost-effectiveness thresholds: pros and cons.Bull World Health Organ. 2016; 94: 925-930Crossref PubMed Scopus (385) Google Scholar Given that Kenya's per-capita GDP in 2016 was $1455, the estimate is easily under the threshold. Ojal and colleagues note that other relatively expensive childhood vaccines such as Haemophilus influenzae type b (Hib) vaccine ($85 per DALY averted) and rotavirus vaccine ($200–400 per DALY averted, depending on the vaccine used), are similarly cost effective.1Ojal J Griffiths U Hammitt LL et al.Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.Lancet Glob Health. 2019; 7: e646-e656Summary Full Text Full Text PDF Scopus (10) Google Scholar Importantly, in view of the fact that only 2% of the DALYs averted come from prevention of morbidity, the researchers' assessment of cost-effectiveness of PCV in Kenya was based almost entirely on the vaccine's ability to prevent deaths.1Ojal J Griffiths U Hammitt LL et al.Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.Lancet Glob Health. 2019; 7: e646-e656Summary Full Text Full Text PDF Scopus (10) Google Scholar Their model relies on reasonable assumptions for the incidence of IPD, the ratio of IPD to pneumonia, the case fatality ratios, and other parameters. However, the degree to which PCV use actually reduces pneumococcal mortality in Kenya, or in any setting, is not well studied and far from clear.5Schuck-Paim C Taylor RJ Alonso WJ Weinberger DM Simonsen L Effect of pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in Brazil: a retrospective observational study.Lancet Glob Health. 2019; 7: e249-e256Summary Full Text Full Text PDF PubMed Scopus (31) Google Scholar An often-cited randomised trial in the Gambia reported a 16% reduction in all-cause mortality among vaccinated children,6Cutts FT Zaman SM Enwere G Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.Lancet. 2005; 365: 1139-1146Summary Full Text Full Text PDF PubMed Scopus (762) Google Scholar but this was a secondary endpoint with a wide confidence interval. Findings of several studies have convincingly documented a significant reduction in IPD and pneumonia incidence, although serotype replacement can erode PCV benefits over time.7Feikin DR Kagucia EW Loo JD et al.Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.PLoS Med. 2013; 10: e1001517Crossref PubMed Scopus (345) Google Scholar However, very few studies have reported on the vaccine's effect on mortality. Results of one recent observational study showed that after PCV10 was introduced in Brazil in 2010, the vaccine caused pneumonia mortality to fall by about 10% nationally by 2014, with larger reductions in strata with lower socioeconomic status.5Schuck-Paim C Taylor RJ Alonso WJ Weinberger DM Simonsen L Effect of pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in Brazil: a retrospective observational study.Lancet Glob Health. 2019; 7: e249-e256Summary Full Text Full Text PDF PubMed Scopus (31) Google Scholar Another important point is that pneumonia claims far more lives than IPD, and pneumonia mortality in Kenya and other lower-income countries was falling steadily long before the PCV programmes started.5Schuck-Paim C Taylor RJ Alonso WJ Weinberger DM Simonsen L Effect of pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in Brazil: a retrospective observational study.Lancet Glob Health. 2019; 7: e249-e256Summary Full Text Full Text PDF PubMed Scopus (31) Google Scholar, 8Institute for Health Metrics and Evaluation (IHME)GBD Compare. IHME, University of Washington, Seattle, WA2018http://vizhub.healthdata.org/gbd-compareDate accessed: December 23, 2018Google Scholar, 9WHOPneumococcal Conjugate Vaccine (PCV) Review of Impact Evidence (PRIME) summary of findings from systematic review.https://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdfDate: October 2017Date accessed: December 23, 2018Google Scholar Indeed, teasing vaccine benefits from a background mortality that is rapidly decreasing due to other factors is a difficult modelling challenge. Many factors surely contributed to the decrease, such as better access to health care (especially antibiotics), improved nutrition, better housing, and hygiene.10Hanf M Nacher M Guihenneuc C Tubert-Bitter P Chavance M Global determinants of mortality in under 5s: 10 year worldwide longitudinal study.BMJ. 2013; 347: f6427Crossref PubMed Scopus (20) Google Scholar It is worth asking whether the funds needed to keep the PCV programme going would be better spent on non-vaccine programmes that address these factors. Getting a clear view of mortality benefits of vaccination is not straightforward in any setting, but it is especially difficult in countries that lack national vital statistics data. Nonetheless, more studies of the mortality benefits of vaccinations in Gavi-transitioning countries are sorely needed, especially when, as in the current study, the perceived cost effectiveness relies almost entirely on the vaccine's mortality benefits. As lower-income countries continue to grow economically, improvements in pneumococcal mortality will probably continue, whether PCV is part of the solution or not. Against that background, these countries must decide whether they can afford the substantial costs of PCV, as well as other new and expensive vaccines. What is needed is a comprehensive evaluation of the affordability and mortality benefits that takes into consideration the dramatic increase in costs for childhood vaccine programmes, as well as creative thinking about what else that money could buy in lower-income countries. No one should doubt that vaccines are powerful tools, but that does not mean that they are always the tool to reach for first. We declare no competing interests. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in KenyaContinuing PCV use is essential to sustain its health gains. Based on the Kenyan GDP per capita of $1445, and in comparison to other vaccines, continued PCV use at full costs is cost-effective (on the basis of the assumption that any reduction in disease will translate to a reduction in mortality). Although affordability is likely to be a concern, our findings support an expansion of the vaccine budget in Kenya. Full-Text PDF Open Access" @default.
• W2912311235 created "2019-02-21" @default.
• W2912311235 creator A5009978154 @default.
• W2912311235 creator A5038664722 @default.
• W2912311235 creator A5051014543 @default.
• W2912311235 date "2019-05-01" @default.
• W2912311235 modified "2023-09-23" @default.
• W2912311235 title "Are expensive vaccines the best investment in low-income and middle-income countries?" @default.
• W2912311235 cites W1987110164 @default.
• W2912311235 cites W2122598469 @default.
• W2912311235 cites W2157583453 @default.
• W2912311235 cites W2557867537 @default.
• W2912311235 cites W2911256353 @default.
• W2912311235 cites W2936439923 @default.
• W2912311235 cites W3176682987 @default.
• W2912311235 doi "https://doi.org/10.1016/s2214-109x(19)30040-3" @default.
• W2912311235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31000121" @default.
• W2912311235 hasPublicationYear "2019" @default.
• W2912311235 type Work @default.
• W2912311235 sameAs 2912311235 @default.
• W2912311235 citedByCount "0" @default.
• W2912311235 crossrefType "journal-article" @default.
• W2912311235 hasAuthorship W2912311235A5009978154 @default.
• W2912311235 hasAuthorship W2912311235A5038664722 @default.
• W2912311235 hasAuthorship W2912311235A5051014543 @default.
• W2912311235 hasBestOaLocation W29123112351 @default.
• W2912311235 hasConcept C144133560 @default.
• W2912311235 hasConcept C162324750 @default.
• W2912311235 hasConcept C17744445 @default.
• W2912311235 hasConcept C199539241 @default.
• W2912311235 hasConcept C27548731 @default.
• W2912311235 hasConcept C2991659908 @default.
• W2912311235 hasConcept C3018472363 @default.
• W2912311235 hasConcept C4249254 @default.
• W2912311235 hasConcept C50522688 @default.
• W2912311235 hasConcept C83864248 @default.
• W2912311235 hasConcept C94625758 @default.
• W2912311235 hasConceptScore W2912311235C144133560 @default.
• W2912311235 hasConceptScore W2912311235C162324750 @default.
• W2912311235 hasConceptScore W2912311235C17744445 @default.
• W2912311235 hasConceptScore W2912311235C199539241 @default.
• W2912311235 hasConceptScore W2912311235C27548731 @default.
• W2912311235 hasConceptScore W2912311235C2991659908 @default.
• W2912311235 hasConceptScore W2912311235C3018472363 @default.
• W2912311235 hasConceptScore W2912311235C4249254 @default.
• W2912311235 hasConceptScore W2912311235C50522688 @default.
• W2912311235 hasConceptScore W2912311235C83864248 @default.
• W2912311235 hasConceptScore W2912311235C94625758 @default.
• W2912311235 hasIssue "5" @default.
• W2912311235 hasLocation W29123112351 @default.
• W2912311235 hasLocation W29123112352 @default.
• W2912311235 hasLocation W29123112353 @default.
• W2912311235 hasOpenAccess W2912311235 @default.
• W2912311235 hasPrimaryLocation W29123112351 @default.
• W2912311235 hasRelatedWork W1515842553 @default.
• W2912311235 hasRelatedWork W1832882728 @default.
• W2912311235 hasRelatedWork W1975287921 @default.
• W2912311235 hasRelatedWork W2032484076 @default.
• W2912311235 hasRelatedWork W2044122011 @default.
• W2912311235 hasRelatedWork W2060988880 @default.
• W2912311235 hasRelatedWork W2104215418 @default.
• W2912311235 hasRelatedWork W237366442 @default.
• W2912311235 hasRelatedWork W2897785451 @default.
• W2912311235 hasRelatedWork W3123667055 @default.
• W2912311235 hasVolume "7" @default.
• W2912311235 isParatext "false" @default.
• W2912311235 isRetracted "false" @default.
• W2912311235 magId "2912311235" @default.
• W2912311235 workType "article" @default.